Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

Kin Man Au, Ashutosh Tripathy, Carolina Pe I. Lin, Kyle Wagner, Seungpyo Hong, Andrew Z. Wang, Steven I. Park

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Non-Hodgkin lymphoma (NHL) is one of the most common types of hematologic malignancies. Pretargeted radioimmunotherapy (PRIT), the sequential administration of a bispecific antibody-based primary tumor-targeting component followed by a radionucleotide-labeled treatment effector, has been developed to improve the treatment efficacy and to reduce the side effects of conventional RIT. Despite the preclinical success of PRIT, clinical trials revealed that the immunogenicity of the bispecific antibody as well as the presence of competing endogenous effector molecules often compromised the treatment. One strategy to improve PRIT is to utilize bio-orthogonal ligation reactions to minimize immunogenicity and improve targeting. Herein, we report a translatable pretargeted nanoradioimmunotherapy strategy for the treatment of NHL. This pretargeting system is composed of a dibenzylcyclooctyne (DBCO)-functionalized anti-CD20 antibody (α-CD20) tumor-targeting component and an azide- and yttrium-90-( 90 Y) dual-functionalized dendrimer. The physicochemical properties of both pretargeting components have been extensively studied. We demonstrated that an optimized dual-functionalized dendrimer can undergo rapid strain-promoted azide-alkyne cycloaddition with the DBCO-functionalized α-CD20 at the physiological conditions. The treatment effector in our pretargeting system can not only selectively deliver radionucleotides to the target tumor cells but also increase the complement-dependent cytotoxicity of α-CD20 and thus enhance the antitumor effects, as justified by comprehensive in vitro and in vivo studies in mouse NHL xenograft and disseminated models.

Original languageEnglish
Pages (from-to)1544-1563
Number of pages20
JournalACS Nano
Volume12
Issue number2
DOIs
Publication statusPublished - 2018 Feb 27

Fingerprint

Bispecific Antibodies
Dendrimers
Azides
Antibodies
Tumors
effectors
Neoplasm Antibodies
Yttrium
antibodies
Alkynes
Cycloaddition
Cytotoxicity
Heterografts
tumors
dendrimers
Cells
Molecules
cycloaddition
alkynes
yttrium

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Au, K. M., Tripathy, A., Lin, C. P. I., Wagner, K., Hong, S., Wang, A. Z., & Park, S. I. (2018). Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano, 12(2), 1544-1563. https://doi.org/10.1021/acsnano.7b08122
Au, Kin Man ; Tripathy, Ashutosh ; Lin, Carolina Pe I. ; Wagner, Kyle ; Hong, Seungpyo ; Wang, Andrew Z. ; Park, Steven I. / Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. In: ACS Nano. 2018 ; Vol. 12, No. 2. pp. 1544-1563.
@article{340eb700c13d4fb49d99ba3f05801e16,
title = "Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma",
abstract = "Non-Hodgkin lymphoma (NHL) is one of the most common types of hematologic malignancies. Pretargeted radioimmunotherapy (PRIT), the sequential administration of a bispecific antibody-based primary tumor-targeting component followed by a radionucleotide-labeled treatment effector, has been developed to improve the treatment efficacy and to reduce the side effects of conventional RIT. Despite the preclinical success of PRIT, clinical trials revealed that the immunogenicity of the bispecific antibody as well as the presence of competing endogenous effector molecules often compromised the treatment. One strategy to improve PRIT is to utilize bio-orthogonal ligation reactions to minimize immunogenicity and improve targeting. Herein, we report a translatable pretargeted nanoradioimmunotherapy strategy for the treatment of NHL. This pretargeting system is composed of a dibenzylcyclooctyne (DBCO)-functionalized anti-CD20 antibody (α-CD20) tumor-targeting component and an azide- and yttrium-90-( 90 Y) dual-functionalized dendrimer. The physicochemical properties of both pretargeting components have been extensively studied. We demonstrated that an optimized dual-functionalized dendrimer can undergo rapid strain-promoted azide-alkyne cycloaddition with the DBCO-functionalized α-CD20 at the physiological conditions. The treatment effector in our pretargeting system can not only selectively deliver radionucleotides to the target tumor cells but also increase the complement-dependent cytotoxicity of α-CD20 and thus enhance the antitumor effects, as justified by comprehensive in vitro and in vivo studies in mouse NHL xenograft and disseminated models.",
author = "Au, {Kin Man} and Ashutosh Tripathy and Lin, {Carolina Pe I.} and Kyle Wagner and Seungpyo Hong and Wang, {Andrew Z.} and Park, {Steven I.}",
year = "2018",
month = "2",
day = "27",
doi = "10.1021/acsnano.7b08122",
language = "English",
volume = "12",
pages = "1544--1563",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "2",

}

Au, KM, Tripathy, A, Lin, CPI, Wagner, K, Hong, S, Wang, AZ & Park, SI 2018, 'Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma', ACS Nano, vol. 12, no. 2, pp. 1544-1563. https://doi.org/10.1021/acsnano.7b08122

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. / Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe I.; Wagner, Kyle; Hong, Seungpyo; Wang, Andrew Z.; Park, Steven I.

In: ACS Nano, Vol. 12, No. 2, 27.02.2018, p. 1544-1563.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

AU - Au, Kin Man

AU - Tripathy, Ashutosh

AU - Lin, Carolina Pe I.

AU - Wagner, Kyle

AU - Hong, Seungpyo

AU - Wang, Andrew Z.

AU - Park, Steven I.

PY - 2018/2/27

Y1 - 2018/2/27

N2 - Non-Hodgkin lymphoma (NHL) is one of the most common types of hematologic malignancies. Pretargeted radioimmunotherapy (PRIT), the sequential administration of a bispecific antibody-based primary tumor-targeting component followed by a radionucleotide-labeled treatment effector, has been developed to improve the treatment efficacy and to reduce the side effects of conventional RIT. Despite the preclinical success of PRIT, clinical trials revealed that the immunogenicity of the bispecific antibody as well as the presence of competing endogenous effector molecules often compromised the treatment. One strategy to improve PRIT is to utilize bio-orthogonal ligation reactions to minimize immunogenicity and improve targeting. Herein, we report a translatable pretargeted nanoradioimmunotherapy strategy for the treatment of NHL. This pretargeting system is composed of a dibenzylcyclooctyne (DBCO)-functionalized anti-CD20 antibody (α-CD20) tumor-targeting component and an azide- and yttrium-90-( 90 Y) dual-functionalized dendrimer. The physicochemical properties of both pretargeting components have been extensively studied. We demonstrated that an optimized dual-functionalized dendrimer can undergo rapid strain-promoted azide-alkyne cycloaddition with the DBCO-functionalized α-CD20 at the physiological conditions. The treatment effector in our pretargeting system can not only selectively deliver radionucleotides to the target tumor cells but also increase the complement-dependent cytotoxicity of α-CD20 and thus enhance the antitumor effects, as justified by comprehensive in vitro and in vivo studies in mouse NHL xenograft and disseminated models.

AB - Non-Hodgkin lymphoma (NHL) is one of the most common types of hematologic malignancies. Pretargeted radioimmunotherapy (PRIT), the sequential administration of a bispecific antibody-based primary tumor-targeting component followed by a radionucleotide-labeled treatment effector, has been developed to improve the treatment efficacy and to reduce the side effects of conventional RIT. Despite the preclinical success of PRIT, clinical trials revealed that the immunogenicity of the bispecific antibody as well as the presence of competing endogenous effector molecules often compromised the treatment. One strategy to improve PRIT is to utilize bio-orthogonal ligation reactions to minimize immunogenicity and improve targeting. Herein, we report a translatable pretargeted nanoradioimmunotherapy strategy for the treatment of NHL. This pretargeting system is composed of a dibenzylcyclooctyne (DBCO)-functionalized anti-CD20 antibody (α-CD20) tumor-targeting component and an azide- and yttrium-90-( 90 Y) dual-functionalized dendrimer. The physicochemical properties of both pretargeting components have been extensively studied. We demonstrated that an optimized dual-functionalized dendrimer can undergo rapid strain-promoted azide-alkyne cycloaddition with the DBCO-functionalized α-CD20 at the physiological conditions. The treatment effector in our pretargeting system can not only selectively deliver radionucleotides to the target tumor cells but also increase the complement-dependent cytotoxicity of α-CD20 and thus enhance the antitumor effects, as justified by comprehensive in vitro and in vivo studies in mouse NHL xenograft and disseminated models.

UR - http://www.scopus.com/inward/record.url?scp=85042662384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042662384&partnerID=8YFLogxK

U2 - 10.1021/acsnano.7b08122

DO - 10.1021/acsnano.7b08122

M3 - Article

C2 - 29361211

AN - SCOPUS:85042662384

VL - 12

SP - 1544

EP - 1563

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 2

ER -